300 mg

DRUG5 trials

Sponsors

Uniwersytet Jagiellonski Collegium Medicum, Uniwersytet Jagiellonski Collegium Medicum, Minoryx Therapeutics S.L., Opella Healthcare Group S.A.S., Woerwag Pharma GmbH & Co. KG, CVI Pharmaceuticals

Conditions

AdrenoleukodystrophyAlcoholic Liver DiseaseChronic Viral Hepatitis BDiabetic sensorimotor polyneuropathy (DSPN)HyperlipidemiaMASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MASHMetabolic Dysfunction-Associated Steatohepatitisaspirin-exacerbated respiratory disease

Phase 1

A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EFFECT ON ORAL LERIGLITAZONE IN MALE HEALTHY SUBJECTS

RecruitingCTIS2025-521508-23-00

Minoryx Therapeutics S.L.Adrenoleukodystrophy

Start: 2025-10-10Target: 73Updated: 2025-10-16

Phase 2

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

CVI PharmaceuticalsHyperlipidemia

Start: 2020-07-15End: 2022-03-15Target: 200Updated: 2020-06-23

Long-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease

CompletedCTIS2024-514602-31-00

Uniwersytet Jagiellonski Collegium Medicum, Uniwersytet Jagiellonski Collegium Medicumaspirin-exacerbated respiratory disease

Start: 2022-12-07End: 2025-01-23Target: 76Updated: 2024-07-01

Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial

Not yet recruitingCTIS2025-521985-82-00

Woerwag Pharma GmbH & Co. KGDiabetic sensorimotor polyneuropathy (DSPN)

Target: 136Updated: 2026-02-18

Phase 3

ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentiale® Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B

Not yet recruitingCTIS2025-521678-32-00

Opella Healthcare Group S.A.S.Alcoholic Liver Disease, Chronic Viral Hepatitis B, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MASH +1

Target: 466Updated: 2025-12-22